There will have been a collective sigh of relief today following the receipt of an open letter to all National Automotive Leasing & Salary Packaging Association members from the Leader of the Opposition Bill Shorten.

The letter from Bill Shorten stated:

“I write regarding car Fringe Benefit Tax arrangements and confirm that a Shorten Labor government will not implement any changes to the Statutory Formula Method relating to employer provided motor vehicles. Labor will retain the current arrangements in relation to all measures regarding salary packaging and related Fringe Benefit Tax measures. There is no difference between our policy and that of the current Turnbull government.”

For a long time now shares of companies involved in the salary packaging industry have been trading at lower than normal earnings multiples due to the uncertainty of what an election and potentially a new government would bring.

But all fears have been cast aside now thanks to Bill Shorten’s letter and investors appear to be fighting to get their hands on shares with exposure to the industry.

At present shares in Smartgroup Corporation Ltd (ASX: SIQ), SG Fleet Group Ltd (ASX: SGF), and McMillan Shakespeare Limited (ASX: MMS) are skyrocketing higher and have so far put on gains of 8%, 7%, and 9%, respectively.

Of the three shares listed above, I believe that McMillan Shakespeare is the best of the lot to be invested in today. Despite the strong gains, the share price is still trading at just under 13x estimated FY 2016 earnings. Furthermore, the company is expected to pay a fully franked estimated 4.5% dividend.

Earnings are expected to grow by a solid 8% per annum for the next couple of years. This is thanks in part to the company being recently appointed as a vehicle leasing partner for the New South Wales government. This appointment means the company becomes one of six companies able to compete for the financing of 22,000 government-owned vehicles.

With fears of any regulatory changes now gone, I believe there is every chance the shares will start to chase down their 52-week high of $14.84 and provide investors strong returns in the process. Much like these shares might do, if you ask me.

Could these just released franked dividend picks turn $15,000 into over $30,000?

When renowned dividend investing pros like Andrew Page issue buy alerts, it pays to listen. Because investors who followed Andrew's recommendation of Australian Pharmaceuticals in early 2015 could've doubled their money in just over a year, turning $15,000 into over $30,000 by the time he recommended they sell and lock in their profits. Chances are you won't want to miss uncovering the names of Andrew's newest share recommendation and short list of 3 dividend Best Buys Now Shares.
So click here to learn more about these potentially life-changing shares.

HOT OFF THE PRESSES: Motley Fool’s #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our https://www.fool.com.au/financial-services-guide">Financial Services Guide (FSG) for more information.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.